1. A crystalline form of a compound of Formula 1: Formula 1 2. A crystalline form of claim 1 wherein said crystalline form is one of anhydrous, monohydrate and sesquahydrate. 3. A crystalline form of claim 1 which has an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 2theta at about 6.0,8.6,9.7,15.4,15.9,17.5, 18.2,18.7, and 21. 4. The crystalline form of claim 3 which has an X-ray powder diffraction pattern 5. A crystalline form of claim 1 which has a differential scanning calorimetry spectrum comprising an event with an onset at about 75 C or about 193 C. 6. The crystalline form of claim 5 which has a differential scanning calorimetry spectrum: 7. A crystalline form of claim 1 which is non-hygroscopic for about 72 hours or to about 7 days when stored at about 87% relative humidity and 25 C. 8. A crystalline form of claim 1 which has an X-ray powder diffraction pattern that exhibits characteristic peaks expressed in 20 at about 6.2,7.6,9.2,9.5,12.3,12.9,14.2, 14.6,17.8, and 19.5. 9. The crystalline form of claim 8 which has an X-ray powder diffraction pattern 10. A crystalline form of claim 1, which has single crystal parameters that are substantially the same as those provided in Table 1. 11. The crystalline form of claim 10 which comprises atoms at atomic positions relative to the origin of the unit cell as set forth in Table 2, bond lengths as set forth in Table 3, or bond angles as set forth in Table 4. 12. The crystalline form of claim 11 which has a single crystal structure: 13. The crystalline form of claim 12 which has a differential scanning calorimetry spectrum: 14. A crystalline form of claim 1 which has an X-ray powder diffraction pattern which exhibits characteristic peaks expressed in 26 at about 5.2,7.4,11.2,11.7,12.3,12.9, 4,16.7, and 17.9. 15. The crystalline form of claim 14 which has an X-ray powder diffraction pattern 16. A crystalline form of claim 1 which has a differential scanning calorimetry spectrum comprising an event with an onset at about 101 C. 17. The crystalline form of claim 16 which has a differential scanning calorimetry spectrum: 18. A pharmaceutical composition comprising a crystalline form of a compound of Formula 1 and a pharmaceutically acceptable carrier. 19. The pharmaceutical composition of claim 18 wherein the crystalline form is one of anhydrous, monohydrate and sesquahydrate. 20. The pharmaceutical composition of claim 18 wherein said pharmaceutical composition is suitable for oral, rectal, parenteral (intravenous, intramuscular), transdermal, buccal, nasal, sublingual, or subcutaneous administration. 21. A process of preparing any one of a crystalline anhydrous, monohydrate, and sesquahydrate form respectively of a compound of Formula 1 which comprises: dissolving an amount of a compound of Formula 1 in one of an anhydrous, nonaqueous and ethyl acetate solvent respectively; cooling the solution to a temperature at which the full amount of the compound of Formula 1 is no longer soluble in the solution; and isolating by filtration any crystals that are formed. 22. A product of the process of claim 21. 23. A method of treating a bacterial or protozoal infection in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a crystalline form of a compound of Formula 1. 24. The method of claim 23 wherein the crystalline form is one of anhydrous, monohydrate, and sesquahydrate form.